Secord, AA, Previs, RA, and Nixon, AB. "Cabozantinib in ovarian clear cell cancers: UnMET expectations." Gynecologic Oncology 150, no. 1 (July 2018): 1-2.
Rebecca A Previs, MD
Education and Training
- M.D., University of Virginia School of Medicine, 2009
Research interests include early phase clinical trials, novel therapeutics, the microenvironment, and personalized medicine. I am working on translating what we learn at the laboratory bench into better therapies for our patients. I am interested in gaining a better understanding of the immune microenvironment to determine how cancer cells evade discovery by our own immune systems.
Selected Grants and Awards
Allen, JK, Armaiz-Pena, GN, Nagaraja, AS, Sadaoui, NC, Ortiz, T, Dood, R, Ozcan, M, Herder, DM, Haemmerle, M, Gharpure, KM, Rupaimoole, R, Previs, RA, Wu, SY, Pradeep, S, Xu, X, Han, HD, Zand, B, Dalton, HJ, Taylor, M, Hu, W, Bottsford-Miller, J, Moreno-Smith, M, Kang, Y, Mangala, LS, Rodriguez-Aguayo, C, Sehgal, V, Spaeth, EL, Ram, PT, Wong, STC, Marini, FC, Lopez-Berestein, G, Cole, SW, Lutgendorf, SK, De Biasi, M, and Sood, AK. "Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction." Cancer Research 78, no. 12 (June 15, 2018): 3233-3242.
Huang, Y, Hu, W, Huang, J, Shen, F, Sun, Y, Ivan, C, Pradeep, S, Dood, R, Haemmerle, M, Jiang, D, Mangala, LS, Noh, K, Hansen, JM, Dalton, HJ, Previs, RA, Nagaraja, AS, McGuire, M, Jennings, NB, Broaddus, R, Coleman, RL, and Sood, AK. "Inhibiting nuclear phospho-progesterone receptor enhances antitumor activity of onapristone in uterine cancer." Molecular Cancer Therapeutics 17, no. 2 (February 1, 2018): 464-473.
Previs, RA, Armaiz-Pena, GN, Ivan, C, Dalton, HJ, Rupaimoole, R, Hansen, JM, Lyons, Y, Huang, J, Haemmerle, M, Wagner, MJ, Gharpure, KM, Nagaraja, AS, Filant, J, McGuire, MH, Noh, K, Dorniak, PL, Linesch, SL, Mangala, LS, Pradeep, S, Wu, SY, and Sood, AK. "Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies." Journal of the National Cancer Institute 109, no. 7 (July 2017).
Huang, Y, Lichtenberger, LM, Taylor, M, Bottsford-Miller, JN, Haemmerle, M, Wagner, MJ, Lyons, Y, Pradeep, S, Hu, W, Previs, RA, Hansen, JM, Fang, D, Dorniak, PL, Filant, J, Dial, EJ, Shen, F, Hatakeyama, H, and Sood, AK. "Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer." Molecular Cancer Therapeutics 15, no. 12 (December 2016): 2894-2904.
Previs, RA, Sood, AK, Mills, GB, and Westin, SN. "The rise of genomic profiling in ovarian cancer." Expert Review of Molecular Diagnostics 16, no. 12 (December 2016): 1337-1351. (Review)
Highley, LL, Previs, RA, Dotters-Katz, SK, Brancazio, LR, and Grotegut, CA. "Cesarean delivery among women with prolonged labor induction." Journal of Perinatal Medicine 44, no. 7 (October 2016): 759-766.
Whiting, N, Hu, J, Zacharias, NM, Lokesh, GLR, Volk, DE, Menter, DG, Rupaimoole, R, Previs, R, Sood, AK, and Bhattacharya, P. "Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer." Journal of Medical Imaging 3, no. 3 (August 10, 2016): 036001-036001.
Rupaimoole, R, Ivan, C, Yang, D, Gharpure, KM, Wu, SY, Pecot, CV, Previs, RA, Nagaraja, AS, Armaiz-Pena, GN, McGuire, M, Pradeep, S, Mangala, LS, Rodriguez-Aguayo, C, Huang, L, Bar-Eli, M, Zhang, W, Lopez-Berestein, G, Calin, GA, and Sood, AK. "Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression." Oncogene 35, no. 33 (August 2016): 4312-4320.
Huang, J, Hu, W, Hu, L, Previs, RA, Dalton, HJ, Yang, X-Y, Sun, Y, McGuire, M, Rupaimoole, R, Nagaraja, AS, Kang, Y, Liu, T, Nick, AM, Jennings, NB, Coleman, RL, Jaffe, RB, and Sood, AK. "Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth." Molecular Cancer Therapeutics 15, no. 6 (June 2016): 1344-1352.